UNSPSC 51172011: Cynarine

This classification denotes a cholagogue or choleretic agent with the molecular formula C25H24O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 85D81U9JAV, chemically known as 1,5-dicaffeoylqunic acid but generally known as cynarine, which bears US NIH Compound Identifier 5281769. European Medicines Agency schedules Cynarine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06870MIG.

UNSPSC 51172011 Cynarine, a Commodity code, encompasses pharmaceutical and health-care testing products and services procured by state agencies, county criminal justice departments, and multistate cooperative purchasing consortia. State and local buyers under this code range from Texas Health and Human Services Commission and county community supervision departments to the Minnesota Multistate Cooperative Purchasing Alliance, which administers purchasing on behalf of participating state and local government facilities across multiple jurisdictions. Recent solicitations reflect a broad procurement scope including drug-testing services, direct-to-manufacturer prescription programs, and generic pharmaceuticals and over-the-counter products distributed through authorized wholesalers, with contracts valued at $600,000 to multi-year agreements spanning two years with optional renewals.

Activity is concentrated in Texas and the Upper Midwest, with the most recent opportunities originating from Collin County, Texas Health and Human Services Commission, and the Minnesota Department of Administration's cooperative purchasing program. Collin County Community Supervision and Corrections Department issued RFP 2026-327 on July 9, 2026, for offender specimen collection and drug testing services with proposals due July 23, 2026, seeking staffing for two collection sites in Plano and McKinney, immunoassay screening with LC/MS/MS or GC/MS confirmation, and alternative testing methodologies; the estimated contract value is $600,000 with a two-year term and three optional one-year renewals commencing September 1, 2026, with an anticipated award date of August 10, 2026. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting capacity and value-based agreements without firm pricing or award values disclosed. The Minnesota Multistate Cooperative Purchasing Alliance issued a Request for Proposal in January 2026 with a March 26, 2026, response deadline for generic multi-source pharmaceuticals and over-the-counter products to be distributed through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson, with contracts effective July 1, 2026, and a two-year initial term with optional extensions through June 30, 2028.